Moreover, we showed that COX-2 expression predicts worse overall survival of patients with IBC, COX-2 regulates self-renewal of CSCs and invasiveness of IBC cells, and COX-2 is required for EGFR regulation of CSC marker-expressing cells, highlighting the clinical implication of targeting COX-2 in IBC. Here, PTGS2 is linked to inflammatory breast carcinoma.